Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Wedbush Sees ~460% Upside in Regulus Therapeutics (RGLS) After Bumping Target to $42
August 5, 2015 1:03 PM EDTWedbush analyst Liana Moussatos reiterated an Outperform rating and boosted her price target on Regulus Therapeutics (NASDAQ: RGLS) to $42.00 (from $41.00) following Q2 results. The analyst projects $139MM cash lasts through 2016 and covers material catalysts.
Moussatos said "With RGLS trading at only... More
Regulus Therapeutics (RGLS) Q2 Revenue Tops Views
August 4, 2015 5:32 PM EDTRegulus Therapeutics (NASDAQ: RGLS) reported Q2 EPS of ($0.41), may not compare to the analyst estimate of ($0.29). Revenue for the quarter came in at $3.8 million versus the consensus estimate of $2.4 million.
For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.
... More